The European Huntington Association, in collaboration with Wave, organized a Webinar on the updates of Select-HD clinical trial for Huntington’s disease.
Dr. Ralf Reilmann, founder of the George-Huntington Institute in Muenster, presented an overview of the SELECT-HD trial, which is looking at the safety of the investigational molecule called WVE-003. After his presentation, we had a Q&A session with Danlin Xu, HD Medical Director at Wave, and Marissa Volpe, HD Program Lead at Wave.